Clinical Trial Detail

NCT ID NCT02026271
Title A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ziopharm
Indications

malignant glioma

glioblastoma multiforme

Therapies

Ad-RTS-IL-12 plus AL

Age Groups: senior adult

No variant requirements are available.